APYX Apyx Medical Corporation - Fundamental Analysis

BULLISH

APYX Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$3.12

Analyst Target

$6.0

+92.3% Upside

52W High

$4.5

52W Low

$0.76

Overview AI Snowflake Price Valuation More metrics Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Unlock key metrics

Market cap, P/E, ROE, margins, leverage and more.

AI Analysis

Confidence Score

85%

Analysis Accuracy

APYX exhibits a weak deterministic health profile with a Piotroski F-Score of 1/9 and no Altman Z-Score, indicating severe financial distress risk and poor operational efficiency. Despite this, the stock shows strong earnings momentum with a 64.3% YoY EPS growth and consistent earnings beats (3/4 in last 4 quarters), supported by a 23.82% average surprise. The company trades at a premium valuation (Price/Book: 20.13, Forward P/E: -8.72) but is priced for high growth, which is reflected in analyst buy recommendations and a 1Y return of +164.4%. The lack of dividend and insider activity suggests no immediate capital return or confidence signal, but the technical trend remains neutral despite recent price volatility.

Key Strengths

Strong earnings growth momentum with 64.3% YoY EPS growth and 44.4% Q/Q improvement

Consistent earnings beat rate (3/4 in last 4 quarters) with an average surprise of 23.82%

High gross margin (62.65%) indicates pricing power and efficient production

Significant 1-year price appreciation (+164.4%) despite historical underperformance

Analyst consensus is buy with a target price of $6.00, implying 92.3% upside

Key Risks

Piotroski F-Score of 1/9 signals extreme financial distress and poor operational health

Negative ROE (-168.13%) and ROA (-10.06%) indicate severe capital inefficiency

Debt/Equity ratio of 6.45 is dangerously high, suggesting over-leveraged balance sheet

No Altman Z-Score available, but the financial health metrics imply distress risk

Negative profit margin (-30.35%) and lack of positive cash flow metrics raise sustainability concerns

AI Fair Value Estimate

Based on comprehensive analysis

$4.25

+36.2% above current price

Performance Snowflake

Multi-dimensional AI analysis across 5 key categories

Unlock AI-Powered Analysis

See Value, Future Performance, Past Performance, Financial Health & Dividend scores

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Unlock Price Charts

View historical price trends and analyst targets

Historical Performance Trends

Long-term financial metrics and growth patterns

Unlock Historical Data

View 3-year revenue, profit margins, and growth trends

Valuation Metrics

Key valuation ratios and pricing indicators

P/E, P/B, P/S, EV/EBITDA and more

Profitability, Growth & Financial Health

Detailed profit margins, ROE, debt ratios, and liquidity metrics

Unlock Detailed Metrics

View ROE, Operating Margin, Debt/Equity, Current Ratio and more

Sector Comparison & Peer Analysis

Compare APYX against industry averages and similar companies

Unlock Sector Insights

See how APYX compares to competitors and industry standards

Insider Trading & Analyst Ratings

Track insider transactions and Wall Street analyst recommendations

Unlock Insider Data

See recent insider buys/sells and analyst price targets

Past News Coverage

Recent headlines mentioning APYX from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends